OverviewSuggest Edit

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
TypePublic
Founded2015
HQWoburn, US
Websitereplimune.com

Latest Updates

Employees (est.) (Dec 2019)104(+23%)
Job Openings3
Share Price (Jun 2020)$25.1
Cybersecurity ratingBMore

Key People/Management at Replimune

Robert Coffin

Robert Coffin

Founder, President and Chief Research & Development Officer, Director
Philip Astley-Sparke

Philip Astley-Sparke

Chief Executive Officer
Jason Rhodes

Jason Rhodes

Director
Sander Slootweg

Sander Slootweg

Director
Otello Stampacchia

Otello Stampacchia

Director
Hy Levistsky

Hy Levistsky

Director
Show more

Replimune Office Locations

Replimune has offices in Woburn and Milton
Woburn, US (HQ)
18 Commerce Way
Woburn, US
500 Unicorn Park Dr 3rd floor
Milton, GB
69-70 Park Dr
Show all (3)

Replimune Financials and Metrics

Replimune Revenue

USD

Net income (FY, 2019)

(30.8m)

EBIT (FY, 2019)

(30.9m)

Market capitalization (29-Jun-2020)

922.5m

Closing stock price (29-Jun-2020)

25.1

Cash (31-Mar-2019)

25.7m

EV

903.4m
Replimune's current market capitalization is $922.5 m.
GBPFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.7m5.7m8.8m

R&D expense

6.9m13.5m22.2m

Operating expense total

9.6m19.2m30.9m

EBITDA

(671.3k)
GBPFY, 2016FY, 2017FY, 2018FY, 2019

Cash

9.7m20.6m17.6m25.7m

Prepaid Expenses

401.0k763.0k3.7m

Current Assets

10.6m22.4m64.7m141.0m

PP&E

115.6k342.0k370.0k12.2m
GBPFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(478.4k)(7.7m)(19.7m)30.8m

Depreciation and Amortization

122.0k109.0k148.0k

Accounts Payable

120.0k

Cash From Operating Activities

(1.4m)(7.1m)(16.0m)(25.4m)
USDFY, 2016

Financial Leverage

1 x
Show all financial metrics

Replimune Operating Metrics

FY, 2018

Patients Reached

150
Show all operating metrics

Replimune Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Replimune Online and Social Media Presence

Embed Graph

Replimune News and Updates

Replimune Announces Pricing of Upsized Public Offering

BOSTON, June 08, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering p…

Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

WOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal fourth quarter and year ended March 31, 2020 …

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

RP1: Four of the first five cutaneous squamous cell carcinoma (CSCC) patients treated in combination with Opdivo® reported to be in response (all ongoing) including two complete responses; registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (…

Replimune Announces Pricing of Public Offering

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 3,678,031 shares of its common stock at a public offering p…

Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update

RP1: Clinical data presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) confirmed expected safety profile and mechanism of action: Efficacy data supports ongoing and expanded programs in cutaneous squamous cell carcinoma (CSCC) and melanoma

Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update

RP1: Initial Data from Phase 1 part of Phase 1/2 clinical trial alone and in combination with nivolumab expected to be presented in the fourth calendar quarter of 2019
Show more

Replimune Blogs

Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference

Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference Content Import Tue, 01/07/2020 - 08:01 Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference January 7, 2020 at 8:00 AM EST This release is a backfill from a News Wire …

Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer

Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer Content Import Mon, 12/09/2019 - 08:01 Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer December 9, 2019 at 8:00 AM EST …

Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference

WOBURN, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke , Executive Chairman and Director of Replimune , will present and

Replimune Announces Proposed Public Offering

BOSTON , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public offering of up to 5,000,000 shares of its common stock.

Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types Mechanism of action confirmed for RP1 alone and in combination with Opdivo Biomarker data suggests RP1 provides broad anti-tumor immune activation WOBURN, Mass. , Nov.

Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

WOBURN, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic ™ platform, today announced it will host an investor event to review the full safety, clinical efficacy, and biomarker
Show more

Replimune Frequently Asked Questions

  • When was Replimune founded?

    Replimune was founded in 2015.

  • Who are Replimune key executives?

    Replimune's key executives are Robert Coffin, Philip Astley-Sparke and Jason Rhodes.

  • How many employees does Replimune have?

    Replimune has 104 employees.

  • Who are Replimune competitors?

    Competitors of Replimune include Mirati Therapeutics, Merrimack Pharmaceuticals and Genocea Biosciences.

  • Where is Replimune headquarters?

    Replimune headquarters is located at 18 Commerce Way, Woburn.

  • Where are Replimune offices?

    Replimune has offices in Woburn and Milton.

  • How many offices does Replimune have?

    Replimune has 3 offices.